Cargando…
Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles
INTRODUCTION: Currently, there are no approved drugs for treating non-alcoholic steatohepatitis (NASH); however, mesenchymal stem cells (MSCs) and their small extracellular vesicles (sEVs), which possess immunomodulatory activities, are potential candidates. This study aimed to develop a mouse model...
Autores principales: | Watanabe, Takayuki, Tsuchiya, Atsunori, Takeuchi, Suguru, Nojiri, Shunsuke, Yoshida, Tomoaki, Ogawa, Masahiro, Itoh, Michiko, Takamura, Masaaki, Suganami, Takayoshi, Ogawa, Yoshihiro, Terai, Shuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society for Regenerative Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232114/ https://www.ncbi.nlm.nih.gov/pubmed/32455155 http://dx.doi.org/10.1016/j.reth.2020.03.012 |
Ejemplares similares
-
Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration
por: Tsuchiya, Atsunori, et al.
Publicado: (2019) -
Chronic inflammation as a molecular basis of nonalcoholic steatohepatitis: role of macrophages and fibroblasts in the liver
por: Itoh, Michiko, et al.
Publicado: (2020) -
Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis
por: Takeuchi, Suguru, et al.
Publicado: (2021) -
Mesenchymal stem cells cultured under hypoxic conditions had a greater therapeutic effect on mice with liver cirrhosis compared to those cultured under normal oxygen conditions
por: Kojima, Yuichi, et al.
Publicado: (2019) -
A novel prostaglandin I(2) agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice
por: Motegi, Satoko, et al.
Publicado: (2022)